Comparative Pharmacology
Head-to-head clinical analysis: BYOOVIZ versus MVASI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BYOOVIZ versus MVASI.
BYOOVIZ vs MVASI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BYOOVIZ (bevacizumab-maly) is a vascular endothelial growth factor (VEGF) inhibitor that binds to VEGF-A and prevents its interaction with receptors VEGFR-1 and VEGFR-2, thereby inhibiting angiogenesis and tumor growth.
Monoclonal antibody that inhibits vascular endothelial growth factor (VEGF), preventing binding to VEGFR-1 and VEGFR-2, thereby inhibiting angiogenesis and tumor growth.
0.5 mg (0.05 mL of 10 mg/mL solution) administered by intravitreal injection once every 4 weeks (monthly). Dose adjustment is not recommended.
5 mg/kg intravenously every 2 weeks for metastatic colorectal cancer; 15 mg/kg intravenously every 3 weeks for non-small cell lung cancer, glioblastoma, renal cell carcinoma, and cervical cancer.
None Documented
None Documented
20 days (range 11–50 days) in patients; supports every-2- or 3-week dosing. Longer half-life in bevacizumab compared to other monoclonal antibodies due to FcRn-mediated recycling.
Approximately 20 days (range 11–50 days); typical dosing interval every 2–3 weeks.
Bevacizumab (BYOOVIZ) is eliminated primarily via proteolytic catabolism, not renal or biliary excretion. No significant intact drug is excreted in urine or feces.
Primarily metabolized via reticuloendothelial system; no significant renal or biliary excretion of intact drug.
Category C
Category C
VEGF Inhibitor
VEGF Inhibitor